<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05069311</url>
  </required_header>
  <id_info>
    <org_study_id>UNUD-CTR-FK240921-001</org_study_id>
    <nct_id>NCT05069311</nct_id>
  </id_info>
  <brief_title>Effects of Multimodal Analgesia on Serum MCP-1, BDNF, and MiRNA-124 in Hysterectomy Surgery</brief_title>
  <official_title>Effects of Multimodal Analgesia on Monocyte Chemoattractant Protein-1, Brain-derived Neurotrophic Factor, and RNA-124 Micro to Acute Pain in Patients Who Underwent Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Udayana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Udayana University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The inflammatory process is the main mechanism in the occurrence of acute postoperative pain.&#xD;
      It is also the main risk for the development of acute pain into persistent pain. Inflammation&#xD;
      occurs in the process of peripheral sensitization and central sensitization with various&#xD;
      inflammatory mediators. Postoperatively, there will be proliferation and activation of&#xD;
      microglia and astrocytes which will then activate inflammatory receptors and signaling&#xD;
      cascades of neurotransmitters, cytokines, and chemokines. There has been a lot of clinical&#xD;
      research evidence that multimodal analgesia can adequately treat acute pain and can prevent&#xD;
      the development of acute postoperative pain into persistent pain and chronic postoperative&#xD;
      pain, but the molecular mechanisms are not fully understood.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Preoperative MCP-1</measure>
    <time_frame>1-hour before surgery</time_frame>
    <description>serum level of MCP-1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preoperative BDNF</measure>
    <time_frame>1-hour before surgery</time_frame>
    <description>serum level of BDNF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Preoperative MiRNA-124</measure>
    <time_frame>1-hour before surgery</time_frame>
    <description>serum level of MiRNA-124</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative MCP-1</measure>
    <time_frame>48-hours after surgery</time_frame>
    <description>serum level of MCP-1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative BDNF</measure>
    <time_frame>48-hours after surgery</time_frame>
    <description>serum level of BDNF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postoperative MiRNA-124</measure>
    <time_frame>48-hours after surgery</time_frame>
    <description>serum level of MiRNA-124</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Inflammation</condition>
  <condition>Inflammatory Response</condition>
  <condition>Acute Pain</condition>
  <condition>Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Hysterectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who undergo surgical hysterectomy that fits inclusion and exclusion criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multimodal analgesia</intervention_name>
    <description>Multimodal analgesia includes the combination of:&#xD;
morphine given by PCA (patient-controlled analgesia) at 1 mg/dose&#xD;
bupivacaine 0.25% and dexmedetomidine 0.5 mcg/mL (total volume of 10 mL) by epidural-catheter bolus given preoperatively&#xD;
bupicavaine 0.125% and dexmedetomidine 0.5 mcg/mL at a 5 mL/hour rate per epidural-catheter given intraoperatively&#xD;
bupivacaine 0.1% and dexmedetomidine 0.5 mcg/mL given by programmed intermittent epidural bolus (PIEB), set to be delivered every one-hour&#xD;
etericoxib 90 mg per oral give two-hours before surgery and then continued until three days post-surgery&#xD;
paracetamol 1 g (intravenously) given on the day of the surgery, continued at 10 mg/kg dose every 8 hours until three days post-surgery</description>
    <arm_group_label>Hysterectomy</arm_group_label>
    <other_name>Group M</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Conventional intravenous analgesia</intervention_name>
    <description>Standard analgesia includes fentanyl 2 mcg/kg (bolus) and morphine given by PCA (patient-controlled analgesia) at 1 mg/dose</description>
    <arm_group_label>Hysterectomy</arm_group_label>
    <other_name>Group C</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled for elective hysterectomy&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical status 1 to 3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  allergy to studied drugs&#xD;
&#xD;
          -  history of chronic pain&#xD;
&#xD;
          -  history of hepatitis, depression, peptic ulcer, or acute myocardial infarction&#xD;
&#xD;
          -  receive intraoperative massive blood transfusion&#xD;
&#xD;
          -  prolonged coagulation&#xD;
&#xD;
          -  body mass index &gt;35 kg/m2&#xD;
&#xD;
          -  patients with neurological deficits&#xD;
&#xD;
          -  taking anti-platelet medications&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sanglah General Hospital</name>
      <address>
        <city>Denpasar</city>
        <state>Bali</state>
        <zip>80114</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <contact>
      <last_name>Made Wiryana</last_name>
      <phone>+62811392171</phone>
      <email>made.wiryana@unud.ac.id</email>
    </contact>
    <investigator>
      <last_name>I Gusti NM Aribawa, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 23, 2021</study_first_submitted>
  <study_first_submitted_qc>October 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Udayana University</investigator_affiliation>
    <investigator_full_name>Christopher Ryalino, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

